[DOI] [PMC free article] [PubMed] [Google Scholar] 91.Glushakova O., Kosugi T., Roncal C., Mu W., Heinig M., Cirillo P., Snchez-Lozada L.G., Johnson R.J., Nakagawa T
Results showed those receiving GLP-1 receptor agonists reported fewer skin-related adverse events compared with those receiving DPP-IVs (PRR = 0.27
The primary endpoint was the overall percent use and change in use over time of GIP/GLP-1 RA, while secondary endpoints included demographic and clinical factors associated with medication use
Hepcidin alleviates LPS-induced ARDS by regulating the ferritin-mediated suppression of ferroptosis
Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1
doi: 10.1186/s12958-023-01126-1 108 HarlevAGuptaSAgarwalA